David Bowtell

Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma.

Ksenija Nesic, Olga Kondrashova, Rachel M Hurley, Cordelia D McGehee, Cassandra J Vandenberg, Gwo-Yaw Ho, Elizabeth Lieschke, Genevieve Dall, Nirashaa Bound, Kristy Shield-Artin, Marc Radke, Ashan Musafer, Zi Qing Chai, Mohammad Reza Eftekhariyan Ghamsari, Maria I Harrell, Damien Kee, Inger Olesen, Orla McNally, Nadia Traficante, undefined Australian Ovarian Cancer Study, et al.

Journal article  |  2021  |  Cancer Res

In high-grade serous ovarian carcinoma (HGSC), deleterious mutations in DNA repair gene RAD51C are established drivers of defectiv..

Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition

Diar Aziz, Neil Portman, Kristine J Fernandez, Christine Lee, Sarah Alexandrou, Alba Llop-Guevara, Zoe Phan, Aliza Yong, Ashleigh Wilkinson, C Marcelo Sergio, Danielle Ferraro, Dariush Etemadmoghadam, David D Bowtell, Violeta Serra, Paul Waring, Elgene Lim, C Elizabeth Caldon

Journal article  |  2021  |  NPJ BREAST CANCER

Basal-like breast cancers (BLBC) are aggressive breast cancers that respond poorly to targeted therapies and chemotherapies. In or..

Abstract 3141: Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer

Aritro Nath, Patrick Cosgrove, Benjamin Copeland, Hoda Mirsafian, Elizabeth Christie, Lance Pflieger, Sumana Majumdar, Mihaela Cristea, Ernest Han, Stephen Lee, Edward Wang, Sian Fereday, Nadia Traficante, Ravi Salgia, Theresa Werner, Adam Cohen, Phillip Moos, Jeffrey Chang, David Bowtell, Andrea Bild

Conference Proceedings  |  2021  |  Tumor Biology

Abstract 1074: Improving efficacy of microtubule inhibitors in the treatment of high-grade serous ovarian cancer and ovarian carcinosarcoma

Cassandra J Vandenberg, Gwo-Yaw Ho, Ksenija Nesic, Elizabeth M Swisher, Sean M Grimmond, Matthew J Wakefield, Holly E Barker, David D Bowtell, Clare L Scott

Conference Proceedings  |  2021  |  Experimental and Molecular Therapeutics

Chaperone-mediated protein degradation (CHAMP): A novel technology for tumor-targeted protein degradation.

Cassandra J Vandenberg, Gwo-Yaw Ho, Ksenija Nesic, Elizabeth M Swisher, Sean M Grimmond, Matthew J Wakefield, Holly E Barker, David D Bowtell, Clare L Scott

Conference Proceedings  |  2021  |  CANCER RESEARCH

Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer.

Aritro Nath, Patrick Cosgrove, Benjamin Copeland, Hoda Mirsafian, Elizabeth Christie, Lance Pflieger, Sumana Majumdar, Mihaela Cristea, Ernest Han, Stephen Lee, Edward Wang, Sian Fereday, Nadia Traficante, Ravi Salgia, Theresa Werner, Adam Cohen, Phillip Moos, Jeffrey Chang, David Bowtell, Andrea Bild

Journal article  |  2021  |  CANCER RESEARCH

The evolution of resistance in high-grade serous ovarian cancer (HGSOC) cells following chemotherapy is only partially understood...

Improving efficacy of microtubule inhibitors in the treatment of high-grade serous ovarian cancer and ovarian carcinosarcoma.

Cassandra J Vandenberg, Gwo-Yaw Ho, Ksenija Nesic, Elizabeth M Swisher, Sean M Grimmond, Matthew J Wakefield, Holly E Barker, David D Bowtell, Clare L Scott

Conference Proceedings  |  2021  |  CANCER RESEARCH

Joint IARC/NCI International Cancer Seminar Series Report: expert consensus on future directions for ovarian carcinoma research

Shama Virani, Glauco Baiocchi, David Bowtell, Citadel J Cabasag, Kathleen R Cho, Renee T Fortner, Keiichi Fujiwara, Jae-Weon Kim, Martin Kobel, Jean-Emmanuel Kurtz, Douglas A Levine, Usha Menon, Barbara M Norquist, Paul DP Pharoah, Anil K Sood, Shelley T Tworoger, Nicolas Wentzensen, Stephen J Chanock, Paul Brennan, Britton Trabert

Journal article  |  2021  |  CARCINOGENESIS

Recently, ovarian cancer research has evolved considerably because of the emerging recognition that rather than a single disease, ..

Classification of molecular subtypes of high-grade serous ovarian cancer by MALDI-Imaging.

Wanja Nikolai Kassuhn, Oliver Klein, Silvia Darb-Esfahani, Hedwig Lammert, Sylwia Handzik, Eliane T Taube, Wolfgang D Schmitt, Oliver Dorigo, David Horst, Carlotta Keunecke, Felix Dreher, Joshy George, David Bowtell, Michael Hummel, Jalid Sehouli, Nils Blüthgen, Hagen Kulbe, Elena Ioana Braicu

Conference Proceedings  |  2021  |  Journal of Clinical Oncology

e17544 Background: High-grade serous ovarian cancer (HGSOC) can be separated by gene expression profiling into four molecular sub..

REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer

Katrin M Sjoquist, David Espinoza, Linda Mileshkin, Sumitra Ananda, Catherine Shannon, Sonia Yip, Jeffrey Goh, David Bowtell, Michelle Harrison, Michael L Friedlander

Journal article  |  2021  |  GYNECOLOGIC ONCOLOGY

BACKGROUND: The primary aim of this study was to evaluate the activity of intraperitoneal bevacizumab (IP-bev) in delaying re-accu..